Articles

Videos

Podcasts

Clinical

There is more to patients with IBD than the physical detriments, with many mental health issues arising from the condition.

Pharmacy Focus Podcast Episode 44: Psychosocial Outcomes in Patients with IBD

Trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant) is a HER2/neu receptor antagonist indicated for early and advanced breast cancer, advanced stomach cancer, and gastroesophageal junction cancer.

Daily Medication Pearl: Trastuzumab 

The research team suggests that healthy weight maintenance throughout adulthood is crucial in preventing colorectal adenoma.

Study: Weight Loss Reduces Risk of Growths Linked to Colorectal Cancer

Small GISTs may cause no symptoms and may grow so slowly that they have no serious effects. 

Pharmacy Clinical Pearl of the Day: Gastrointestinal Stromal Tumors 

The continued approval for this indication may be subject upon verification and description of clinical benefit in a confirmatory trial.

Dostarlimab-gxly Receives FDA Accelerated Approval for Adult Patients with dMMR Recurrent, Advanced Solid Tumors

Nivolumab (Opdivo; Bristol Myers Squibb) is FDA approved for 11 cancer indications, with the most recent approval for use in combination with certain chemotherapy for the initial treatment of gastric cancer.

Oncology Overview: Taking a Closer Look at Nivolumab Immunotherapy

Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.

Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Bemarituzumab Shows Promise in Gastric, Gastroesophageal Junction Cancers 

Median disease-free survival was twice as long in patients who received nivolumab compared to patients who received a placebo.

FDA Approves Nivolumab for Completed Resected Esophageal, Gastroesophageal Junction Cancer

Nivolumab is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival compared to chemotherapy alone in this patient population.

FDA Approves Nivolumab in Combination with Chemotherapy for Advanced, Metastatic Gastric Cancer

® Gastrointestinal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur in digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus, and biliary system.